Skip to content
10-K

Annual Report

Bioventus Inc. BVS

0001628280-25-011831

← back to feed
Filed
Mar 11, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt FY 2024 · Dec 31, 2023 $367M
Short Term Debt FY 2024 · Dec 31, 2023 $27.85M
Cash And Equivalents FY 2024 · Dec 31, 2023 $36.96M
Stockholders Equity FY 2024 · Dec 31, 2023 $173.59M
Current Liabilities FY 2024 · Dec 31, 2023 $175.5M
Total Liabilities FY 2024 · Dec 31, 2023 $589.79M
Current Assets FY 2024 · Dec 31, 2023 $268M
Total Assets FY 2024 · Dec 31, 2023 $810.91M
Shares Diluted FY 2024 · Dec 31, 2022 61.39M sh
Capex restated FY 2024 · Dec 31, 2022 $1.48M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$13.54M
Eps Diluted FY 2024 · Dec 31, 2022 −$2.59
Eps Basic FY 2024 · Dec 31, 2022 −$2.59
Sga Expense restated FY 2024 · Dec 31, 2022 $332.13M
Rd Expense restated FY 2024 · Dec 31, 2022 $23.85M
Net Income FY 2024 · Dec 31, 2022 −$158.7M
Operating Income restated FY 2024 · Dec 31, 2022 −$167.23M
Gross Profit FY 2024 · Dec 31, 2022 $331.08M
Cost Of Revenue FY 2024 · Dec 31, 2022 $181.04M
Revenue FY 2024 · Dec 31, 2022 $512.12M